Cranberry and Quillaja on Symptoms of Uncomplicated UTI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the effects of cranberry and quillaja capsules on symptoms of uncomplicated urinary tract infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Measurement of Urinary Catabolites of PACs as Biomarkers of Consumption of Cranberry Extracts

NCT02087735

Urinary Tract Infections

COMPLETED PHASE1

Cranberry on Urinary Tract Infections

NCT01881165

Urinary Tract Infection

WITHDRAWN PHASE4

Cranberry Extract and Urinary Infection Prevention: a Clinical Trial

NCT02572895

Urinary Tract Infections

UNKNOWN PHASE1

Uromune in Treating Recurrent Urinary Tract Infections in Women

NCT04096820

Recurrent Uti

TERMINATED PHASE2

Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products

NCT01687114

Urinary Tract Infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Urinary tract infection (UTI) is one of the most common bacterial infections in humans and it disproportionately affects women. Currently there are only a few alternatives to antibiotics for treatment of UTI. Although symptomatic relief occurs more quickly in women treated with oral antibiotics for uncomplicated UTIs, patients appear to successfully resolve their UTI without antibiotic therapy. While antibiotics are the mainstay of therapy, there are growing concerns about collateral effects impacting healthy microbiomes and anti-bacterial resistance patterns. Recent estimates from the CDC indicate that more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result.

The proposed research fills a key knowledge gap that will be critical in determining the role of a non-antibiotic substance with the potential to treat UTIs by modulating the urinary and gut microbiome to restore health and minimize the reliance on traditional antibiotic therapy while also preventing antibiotic resistance. In addition, this study will provide early evidence of the short-term symptom and urinary and gut microbiome changes following ingestion of two botanical food substances (cranberry and quillaja) that have the potential for beneficial effects on the microbiome and UTI symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Tract Infections UTI UTI - Lower Urinary Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open label, single site, single group prospective cohort study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cranberry and Quillaja

one 450mg cranberry capsule and one 50mg quillaja capsule in the morning and evening for 14 days.

Group Type EXPERIMENTAL

Pacran and Sapnov P quillaja

Intervention Type OTHER

Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pacran and Sapnov P quillaja

Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cranberry Quillaja Pacran Naturex Sapnov P Quillaia extract type II

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pre-menopausal women 18 years and over
2. Presenting with typical symptoms of an uncomplicated UTI
3. Positive leukocyte or nitrite on in-office urine dipstick confirmed
4. Able to swallow capsules
5. Willing and able to fill out/ answer questionnaires and comply with the study requirement
6. Willing to initiate clinically prescribed antibiotic therapy (typically 5-day antibiotic).
7. Provided written informed consent
8. BMI \>17.5kg m2 and \<35kg m2

Exclusion Criteria

1. Regular use of Vaccinium containing products (e.g. all forms of blueberries, cranberries, bilberry, lingonberry etc. i.e. fruit, dried fruit, pills, juices or supplements) within 28 days of Day 1,
2. Allergy to cranberry, tree bark, or quillaja.
3. Use of any antibacterial supplements or products, that in the opinion of the Medical Investigator may interfere with the study outcomes, within 28 days of Day 1
4. A history of \>5 UTIs in the last 6 months (confirmed by self-report or health professional)
5. Use of antibiotics or antibiotics for prophylaxis to treat a UTI within 28 days of Day 1
6. Women of child bearing potential not willing to use adequate and effective methods of contraception throughout the study, in the opinion of the Investigator
7. Positive urine dipstick pregnancy test at screening on Day 1, currently pregnant and/or breastfeeding
8. History of an adverse reaction or known hypersensitivity or suspected allergy to the investigational product ingredients
9. History of pyelonephritis or reflux
10. Presence of an intermittent or indwelling urinary catheter
11. Anatomical abnormalities of the urinary tract (self-reported)
12. History of or known clinically significant renal or urological disease (self-reported), at the discretion of the investigator
13. History of or known clinically significant cardiac disease, at the discretion of the investigator
14. History of or known clinically significant liver disease, at the discretion of the investigator
15. History of or known clinically significant gastrointestinal disease, at the discretion of the investigator
16. History of or known metabolic disorder or diabetes
17. History of or known incomplete emptying of bladder
18. History or presence of alcohol or illicit drug abuse, any surgical history, clinical condition or organ dysfunction that in the opinion of the Medical Investigator may affect the participant's ability to participate in the study or the study results
19. Currently hospitalized or any planned hospitalizations within the study period.
20. Immunocompromised participants or participants receiving immunosuppressive medication
21. Currently taking warfarin or has received Warfarin within 28 days of Day 1
22. Received an investigational drug within 28 days of Day 1 (pills, juices or supplements)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No